Just one week after Abbott (NYSE:ABT) said it inked a deal with Bigfoot Biomedical to develop an automated diabetes management system, CEO Miles White provided more insight into the company’s excitement over the artificial pancreas space in an earnings call with analysts.
“It’s a fairly clever service and approach that I think will create, not just an alternative that makes the management of the disease or management of someone’s insulin easier, but I think the value proposition of it is going to be pretty compelling,” he said, referencing Bigfoot’s insulin delivery platform.
Get the full story at our sister site, Drug Delivery Business News.
The post Abbott’s CEO: Bigfoot Biomedical and the evolving diabetes market appeared first on MassDevice.
from MassDevice http://ift.tt/2tNEDVp
Cap comentari:
Publica un comentari a l'entrada